-- 百思买（Best Buy，股票代码：BBY）周三宣布，科里·巴里（Corie Barry）将卸任这家电子产品零售商的首席执行官一职，公司内部人士杰森·邦菲格（Jason Bonfig）将接任。 首席客户、产品和物流官邦菲格将接替巴里，巴里在10月底卸任首席执行官后，将继续留在百思买担任顾问六个月。 邦菲格于1999年加入公司，担任库存分析师，负责商品销售、电子商务、市场营销和供应链等领域。他还负责百思买加拿大分公司和公司的零售媒体网络。 董事长大卫·肯尼（David Kenny）在一份声明中表示：“我们相信，杰森是合适的领导者，他能够以紧迫感和创新理念加速业务发展，并为公司及其股东创造有意义的增长。” 巴里自2019年以来一直担任百思买首席执行官。 该公司股价周三下跌5.1%。 今年3月，百思买公布了2026财年盈利预期，预计每股收益将从上年同期的6.37美元增长至6.43美元。截至1月31日的财年，由于同店销售额同比增长，公司营收从415.3亿美元增至416.9亿美元。
Price: $63.31, Change: $-3.29, Percent Change: -4.93%
Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.
Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%
BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%